Side-by-side · Research reference

Follistatin-344vsGDF-8

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED4/58 cited

BAnimal-StrongHUMAN-REVIEWED23/48 cited

Follistatin-344

Myostatin/Activin Antagonist · Research Use

15–25%FST/MSTN ratio ↑

344 AACirculating isoform

ResearchPhase status

Research · No approved protocol

GDF-8

TGF-β Superfamily · Negative Muscle Regulator

15–20%Muscle mass gain (MSTN−/−)

↓ AdiposityFat reduction (loss-of-function)Herman 2026 Jacquez 2026

No adversePhenotype (genetic null)Jacquez 2026

Not administered — research target for inhibition

01Mechanism of Action

Parameter

Follistatin-344

GDF-8

Primary target

Myostatin (MSTN/GDF-8) and Activin A

Activin type II receptors (ActRIIA/B) on skeletal muscleIglesias 2026

Pathway

FST-344 binds MSTN/Activin → prevents ActRIIB receptor engagement → disinhibits muscle anabolism

MSTN → ActRII/TGFBR1 → Smad2/3 signaling → muscle protein synthesis suppression

Downstream effect

Elevated follistatin/myostatin ratio, increased muscle protein synthesis, attenuated muscle atrophy signalingJeong 2026

Restricts muscle hypertrophy, limits satellite cell activation, increases proteolysis via ubiquitin-proteasome and autophagy pathwaysGong 2026 Iglesias 2026

Feedback intact?

Yes — indirect antagonist, preserves endogenous regulation

Yes — part of muscle-pituitary endocrine axis; muscle-derived MSTN influences FSH synthesisIglesias 2026

Origin

Endogenous glycoprotein, 344-AA isoform lacking heparin-binding domain (vs FST-315)

Endogenous myokine secreted by skeletal muscle; circulates systemically as latent complexIglesias 2026

Antibody development

Not documented in available trials (endogenous protein)

—

02Dosage Protocols

Parameter

Follistatin-344

GDF-8

Clinical protocol

None — no approved dosing regimen

Follistatin-344 measured as endogenous biomarker, not administered exogenously in cited trials.

—

Research context

Endogenous modulation via exercise + nutrition

Resistance training + EAA intake elevated FST/MSTN ratio by 15–25% in 12-week RCT (older women).

—

Evidence basis

Human observational / biomarker studies

—

Half-life

Not established

Circulating isoform; lacks tissue-binding domain of FST-315.

—

Clinical use

—

None — MSTN is a research target for inhibition, not a therapeutic peptide administered to humans

Sold by research suppliers (e.g., CertaPeptides) for in vitro / animal studies only.

Inhibition strategies

—

Monoclonal antibodies, VLP-based active immunotherapy, gene editing (CRISPR)

VLP immunogen (MS2.87-97)

—

Active immunization protocol in mice — elicits anti-MSTN antibodies without GDF11 cross-reactivityJacquez 2026

Reduces body fat, increases muscle mass and grip strength; no major safety concerns in animal models.Jacquez 2026

Dual immunization (MSTN + Activin A)

—

Combined active immunization in GH-deficient miceMansoor 2026

Improves skeletal muscle performance beyond single-target inhibition.Mansoor 2026

Gene editing outcomes

—

Precision CRISPR edits produce double-muscle phenotype, improved carcass quality in livestock

Pleiotropic effects on metabolism, reproduction, and welfare require systematic evaluation.

03Metabolic / Fat Loss Evidence

Parameter

Follistatin-344

GDF-8

Primary target

Muscle mass preservation, not direct lipolysis

—

Indirect fat effect

Increased lean mass → elevated resting metabolic rate

Not primary mechanism. Muscle-sparing during deficit.

—

Clinical evidence

Lorcaserin trial (6 mo) showed no MAFI axis changes during fat lossRamirez-Cisneros 2026

Suggests follistatin not primary driver of fat loss in weight-reduction interventions.

—

GLP-1RA studies

Liraglutide (35 days) — no significant MAFI axis modulation despite fat/lean changes

—

Primary mechanism

—

MSTN loss-of-function reduces fat accumulation independent of muscle mass effects

Human genetic evidence

—

Humans with MSTN function-disrupting variants have increased muscle mass, strength, and reduced adiposityHerman 2026

Animal model outcomes

—

VLP-immunized mice: reduced age-associated weight gain, significantly lower body fat by DEXAJacquez 2026

Adipose-muscle crosstalk

—

MSTN modulates myostatin-TAZ signaling; inhibition shifts adipose expansion toward hyperplasiaLi 2026

Metabolic benefits

—

Improved metabolic health in genetic MSTN null modelsJacquez 2026

Age-related effects

—

MSTN upregulation linked to age-dependent muscle atrophy and fat accumulation

04Side Effects & Safety

Parameter

Follistatin-344

GDF-8

Clinical safety data

None — no human exogenous administration trials in literature

—

Theoretical risks

Excessive myostatin inhibition → muscle overgrowth, impaired glucose tolerance

Based on myostatin-null animal models and clinical myostatin inhibitor trials.

—

Endogenous elevation (exercise)

No adverse effects reported in 12-week resistance + EAA trials

—

Cancer risk (theoretical)

Myostatin inhibition may promote tumor growth in malignancy (preclinical data)

—

Regulatory status

Not approved for human use — research peptide only

—

Genetic null phenotype

—

No known adverse phenotypes in humans or mice with MSTN loss-of-functionJacquez 2026

Antibody cross-reactivity risk

—

Non-selective inhibitors may block GDF11, affecting cardiac and neural function

VLP immunotherapy safety

—

No major safety concerns in mice; rare hypersensitivity possibleJacquez 2026

Echocardiography

—

No cardiac abnormalities detected in MSTN-immunized miceJacquez 2026

Pleiotropic effects (gene editing)

—

MSTN editing may affect reproductive performance, metabolic homeostasis, and animal welfare

Assay variability

—

Circulating MSTN levels often fail to mirror intramuscular changes; clinical interpretation challengingIglesias 2026

Absolute Contraindications

Follistatin-344

·Active malignancy
·No approved protocol — research use only

GDF-8

·Not applicable — MSTN is not administered as a therapeutic agent

Relative Contraindications

Follistatin-344

·Insulin resistance / Type 2 diabetes (monitor glucose)
·Pregnancy / lactation (unknown safety profile)

GDF-8

·Inhibition strategies contraindicated in conditions requiring maintained muscle proteostasis (theoretical)

05Administration Protocol

Parameter

Follistatin-344

GDF-8

1. Regulatory status

Follistatin-344 is not approved for human administration. All cited studies measure endogenous serum follistatin as a biomarker, not as an exogenous therapeutic agent.

GDF-8 (myostatin) is not administered to humans. It is studied as a target for inhibition using monoclonal antibodies, active immunotherapy (VLP-based vaccines), or gene editing (CRISPR). Research-grade peptide supplied by vendors like CertaPeptides is intended for in vitro and animal studies only.

2. Endogenous modulation

Resistance exercise combined with essential amino acid (EAA) supplementation elevated the follistatin/myostatin ratio by 15–25% in 12-week randomized trials. Protein intake (1.2–1.5 g/kg/day) synergizes with training to upregulate endogenous follistatin.

Clinical development focuses on blocking MSTN activity via: (1) neutralizing monoclonal antibodies targeting mature MSTN or ActRII receptors; (2) active immunotherapy generating endogenous anti-MSTN antibodies (e.g., MS2.87-97 VLP platform); (3) precision gene editing to disrupt MSTN expression in livestock or therapeutic contexts.

3. Measurement context

Serum follistatin and follistatin/myostatin ratio are used diagnostically in sarcopenia screening and as biomarkers of muscle anabolic balance in clinical trials.

MS2.87-97 VLP administered to mice elicits anti-MSTN antibodies targeting a discrete epitope in mature MSTN protein. Immunization schedule and dose optimized for sustained antibody response without GDF11 cross-reactivity. No human protocols established.Jacquez 2026

4. Research consideration

Gene therapy and recombinant follistatin delivery are under preclinical investigation for muscular dystrophy and sarcopenia. No human safety or efficacy data for exogenous FST-344 administration.

CRISPR-mediated MSTN knockout produces double-muscle phenotype in livestock (cattle, swine, sheep). Ethical frameworks and welfare assessments required; pleiotropic effects on reproduction, metabolism, and health must be systematically evaluated before human translation.

06Stack Synergy

Follistatin-344

+ BPC-157

Multi-pathway

View BPC-157 →

Follistatin-344 (myostatin antagonist) and BPC-157 (tissue repair peptide) address complementary pathways in muscle recovery. FST-344 promotes muscle protein synthesis by disinhibiting myostatin signaling, while BPC-157 accelerates healing of tendons, ligaments, and microtears via angiogenesis and collagen synthesis. Combined, they may support both hypertrophy and structural repair during high-volume training or injury recovery.

Follistatin-344: No approved protocol — endogenous modulation via resistance exercise + EAA
BPC-157: 250–500 mcg SQ · twice daily · near injury site or systemic
Duration: 4–8 weeks
Primary benefit: Muscle hypertrophy + accelerated soft tissue repair

+ TB-500

Moderate

View TB-500 →

TB-500 (thymosin beta-4 fragment) promotes cell migration, angiogenesis, and anti-inflammatory signaling in muscle and connective tissue. Follistatin-344's anabolic signaling may synergize with TB-500's regenerative effects during muscle damage or overtraining, particularly in older adults where both myostatin inhibition and tissue repair are rate-limiting.

Follistatin-344: Endogenous upregulation (resistance training + protein)
TB-500: 2–5 mg SQ · twice weekly · loading phase 4 weeks, then maintenance
Frequency: Twice weekly TB-500, daily training stimulus for FST
Primary benefit: Enhanced recovery, reduced inflammation, muscle growth support

GDF-8

— no documented stacks